ZEALAND PHARMA A/S: Financial statements 2025
CVR: 20045078
Source: annual report 2025, Danish Business Authority
01/01/2025 – 31/12/2025
ZEALAND PHARMA A/S (CVR 20045078) has filed annual accounts for 2025. In 2025, the company reported revenue of DKK 9,214,860,000 and a net result of DKK 6,455,008,000 compared with DKK -1,078,828,000 the year before. That is an increase of 14,598.9% compared with the year before. The profit margin was 70%. Equity in the 2025 report amounted to DKK 14,830,613,000. The solvency ratio was 93%. The company had 418 employees in the financial year.
- Revenue
- DKK 9,214,860,000
- Gross Profit
- DKK 9,214,044,000
- Profit/Loss
- DKK 6,455,008,000
- Equity
- DKK 14,830,613,000
- Total Assets
- DKK 15,948,798,000
- Employees
- 418
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2025 | 9.2B | 9.2B | 6.5B | 14.8B | 418 |
| 2024 | 62.7M | 54.8M | -1.1B | 8.6B | 235 |
| 2023 | 342.8M | 323.6M | -703.7M | 1.6B | 235 |
| 2022 | 104M EUR | 104M EUR | -1.2B EUR | 815.9M EUR | 247 |
| 2021 | 292.6M | 173.8M | -1B | 927.8M | 346 |
Official annual report
How creditworthy is ZEALAND PHARMA A/S?
See the CDS score and get a full credit report with recommended credit limit and payment terms.
Read about the CDS scoreEvents in 2025
ZEALAND PHARMA A/S has published its interim report for the period January 1, 2025 to September 30, 2025.
ZEALAND PHARMA A/S has published its interim report for the period January 1, 2025 to June 30, 2025.
ZEALAND PHARMA A/S has published its interim report for the period January 1, 2025 to March 31, 2025.
ZEALAND PHARMA A/S has published its annual report for 2024. Revenue came to DKK 62,691,000, and the net result was DKK -1,078,828,000.
About ZEALAND PHARMA A/S
ZEALAND PHARMA A/S is a Danish company of the type Aktieselskab based in Søborg, founded in 1997. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The company was previously named ZEALAND PHARMACEUTICALS A/S and PEPTIDE PROBE TECHNOLOGIES ApS. The management consists of Adam Sinding Steensberg and Henriette Wennicke. The board consists of Alf Gunnar Martin Nicklasson (chair), Kirsten Aarup Drejer, Adam Krisko Nygaard and Anneline Nansen. The company's owners include ZEALAND PHARMA A/S, Van Herk Investments B.V. and Van Herk Management Services B.V.. The company has 575 employees (2026). In 2025, the company reported revenue of DKK 9,214,860,000 and a net result of DKK 6,455,008,000 compared with DKK -1,078,828,000 the year before. Equity in the 2025 report amounted to DKK 14,830,613,000.
